Zacks Research Has Bullish Forecast for JNJ FY2025 Earnings

Johnson & Johnson (NYSE:JNJ - Free Report) - Investment analysts at Zacks Research lifted their FY2025 earnings per share estimates for shares of Johnson & Johnson in a research report issued on Wednesday, April 30th. Zacks Research analyst K. Shah now expects that the company will earn $10.59 per share for the year, up from their previous estimate of $10.55. The consensus estimate for Johnson & Johnson's current full-year earnings is $10.58 per share. Zacks Research also issued estimates for Johnson & Johnson's Q4 2025 earnings at $2.45 EPS, Q1 2026 earnings at $2.65 EPS, Q2 2026 earnings at $2.72 EPS, Q3 2026 earnings at $2.76 EPS, FY2026 earnings at $10.91 EPS, Q1 2027 earnings at $2.83 EPS and FY2027 earnings at $11.73 EPS.

Several other research analysts have also recently issued reports on JNJ. Stifel Nicolaus cut their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Sanford C. Bernstein restated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Bank of America lowered their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a report on Thursday, April 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $171.82.

Johnson & Johnson Stock Performance

NYSE JNJ traded up $1.63 during trading on Friday, reaching $156.09. The company's stock had a trading volume of 5,973,317 shares, compared to its average volume of 7,885,287. The business's fifty day moving average price is $158.85 and its 200-day moving average price is $154.61. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market cap of $375.56 billion, a price-to-earnings ratio of 23.47, a P/E/G ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be given a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.33%. Johnson & Johnson's dividend payout ratio is 57.84%.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company's stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently modified their holdings of JNJ. Sulzberger Capital Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter valued at $453,000. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $949,000. Horan Securities Inc. raised its holdings in Johnson & Johnson by 1.3% during the fourth quarter. Horan Securities Inc. now owns 7,178 shares of the company's stock worth $1,038,000 after acquiring an additional 90 shares in the last quarter. Strategic Financial Concepts LLC boosted its position in Johnson & Johnson by 57.9% during the fourth quarter. Strategic Financial Concepts LLC now owns 3,467 shares of the company's stock valued at $501,000 after purchasing an additional 1,271 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Johnson & Johnson during the 3rd quarter worth approximately $69,859,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.